Form 4 for IDXX Idexx Laboratories
Accepted 2025-08-12 00:00:00 ET · period of report 2025-08-08 · accession 0000874716-25-000134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-12 | 2025-08-08 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $598.49 | +183 | 83.5K | +0.2% | +$109.5K |
| D | 2025-08-12 | 2025-08-08 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -183 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-08 | M | A | 183 | $598.49 | 83,494.30 | D | — | — | |
| 2 | Derivative | Premium Incentive Stock Option (right-to-buy) | 2025-08-08 | M | D | 183 | — | 0 | D | $598.49 · — to 2031-02-13 | 183 Common Stock | (F2) Not applicable. (F1) Grant of option at a 110% premium to the closing price of Issuer common stock on the Nasdaq Global Select Market on February 12, 2021 to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025. |